Related Experiment Video

Updated: Aug 15, 2026

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
10:35

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

Expression of IL-17 mRNA in ovarian cancer

T Kato1, H Furumoto, T Ogura

  • 1Department of Obstetrics and Gynecology, University of Tokushima, School of Medicine, 3-18-15 Kuramoto-cho, Tokushima, 770-8503, Japan.

Biochemical and Biophysical Research Communications
|June 13, 2001
PubMed

Insights

Interleukin-17 (IL-17) promotes tumor growth by stimulating blood vessel formation in ovarian cancer. This study found IL-17 mRNA in most ovarian tumors, correlating with higher microvascular density.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Interleukin-17 (IL-17) is recognized as a pro-inflammatory cytokine.
  • Previous research indicated IL-17 functions as an angiogenic factor, promoting tumor growth in murine models.

Purpose of the Study:

  • To investigate the expression of IL-17 mRNA in human ovarian cancer tissues.
  • To determine the relationship between IL-17 expression and tumor angiogenesis, specifically microvascular density, in ovarian cancer.

Main Methods:

  • Reverse Transcription Polymerase Chain Reaction (RT-PCR) was employed to detect IL-17 mRNA expression.
  • Microvascular density was assessed in tumor tissues.

Main Results:

  • IL-17 mRNA was detected in 11 out of 17 (64.7%) ovarian cancer samples.
  • Tumors expressing IL-17 exhibited significantly higher microvascular density (173.4 +/- 55.1/mm(2)) compared to IL-17 negative tumors (107.7 +/- 57.8/mm(2)).
  • No significant correlation was found between IL-17 expression and clinicopathological parameters.

Conclusions:

  • Interleukin-17 (IL-17) is expressed in a substantial percentage of ovarian cancers.
  • IL-17 plays a role in promoting tumor angiogenesis in ovarian cancer.
  • IL-17 expression does not appear to be associated with clinicopathological features in this cohort.

More Related Videos

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...